Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CLGN 
Collplant Biotechnologies Ltd (CLGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: CLGN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -55.46% | Avg. Invested days 15 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 17.55M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 1 | Beta 0.86 | 52 Weeks Range 1.32 - 5.48 | Updated Date 06/29/2025 |
52 Weeks Range 1.32 - 5.48 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.21 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -80.2% |
Management Effectiveness
Return on Assets (TTM) -38.34% | Return on Equity (TTM) -75.27% |
Valuation
Trailing PE - | Forward PE 15.55 | Enterprise Value 9656099 | Price to Sales(TTM) 7.1 |
Enterprise Value 9656099 | Price to Sales(TTM) 7.1 | ||
Enterprise Value to Revenue 3.91 | Enterprise Value to EBITDA -5.97 | Shares Outstanding 12716000 | Shares Floating 7651729 |
Shares Outstanding 12716000 | Shares Floating 7651729 | ||
Percent Insiders 10.16 | Percent Institutions 12.23 |
Analyst Ratings
Rating 1 | Target Price 12 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Collplant Biotechnologies Ltd
Company Overview
History and Background
Collplant Biotechnologies Ltd. was founded in 2004, focusing on recombinant human collagen-based regenerative and aesthetic medicine products. It leverages its BioCollagen technology for tissue repair products.
Core Business Areas
- Regenerative Medicine: Development and commercialization of products for tissue repair and regeneration, including orthopedic and wound healing applications.
- Aesthetic Medicine: Development of dermal fillers and other aesthetic products based on recombinant human collagen.
Leadership and Structure
Yehiel Tal is the CEO. The company has a board of directors and operates with distinct research, development, and commercial departments.
Top Products and Market Share
Key Offerings
- VerteOss: A bone void filler used in orthopedic surgeries. Market share is still developing; specific figures are not readily available. Competitors include Medtronic (MDT), Stryker (SYK), and Johnson & Johnson (JNJ) with their bone graft substitutes.
- rhCollagen: Recombinant human collagen used as a raw material for various applications, including medical and cosmetic products. Market share not readily available; faces competition from bovine and porcine collagen products and synthetic alternatives. Examples of competition are Integra LifeSciences (IART) and Zimmer Biomet (ZBH)
Market Dynamics
Industry Overview
The regenerative medicine industry is growing, driven by aging populations and increasing demand for minimally invasive procedures. The market is competitive, with established players and emerging biotechnology companies.
Positioning
Collplant is positioned as an innovator in recombinant human collagen technology, differentiating itself through its plant-based production platform. It aims to capture market share through partnerships and product development.
Total Addressable Market (TAM)
The total market value for regenerative medicine is estimated to be in the tens of billions of dollars and continue to grow. Collplant aims to capture a portion of this market through its proprietary technology and product pipeline.
Upturn SWOT Analysis
Strengths
- Proprietary rhCollagen technology
- Plant-based production platform
- Strategic partnerships
- Potential for innovative products
Weaknesses
- Limited commercial product portfolio
- Reliance on partnerships
- High research and development costs
- Negative earnings and negative cash flow
Opportunities
- Expanding regenerative medicine market
- Potential for new product applications
- Geographic expansion
- Partnerships with larger companies
Threats
- Competition from established players
- Regulatory hurdles
- Technological advancements by competitors
- Economic downturn
Competitors and Market Share
Key Competitors
- MDT
- SYK
- JNJ
- IART
- ZBH
Competitive Landscape
Collplant is a smaller player compared to its competitors, focusing on innovative technology. It competes on product differentiation and strategic partnerships.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been dependent on partnerships and product approvals. More specific data needs to be based on actual revenues.
Future Projections: Analyst projections will vary. The company expects to grow due to VerteOss sales and new product development.
Recent Initiatives: Focus on expansion of VerteOss sales, exploring new rhCollagen applications.
Summary
Collplant Biotechnologies Ltd. is an innovative company with a unique technology platform. While the company has promising technology, it currently faces significant financial challenges and is heavily reliant on partnerships. Its strengths lie in its proprietary rhCollagen, but it must overcome commercialization hurdles and competition to achieve sustained growth. Investors should closely monitor their progress in sales of VerteOss and other pipeline projects.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Collplant Biotechnologies Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-01-30 | CEO & Director Mr. Yehiel Tal | ||
Sector Healthcare | Industry Biotechnology | Full time employees 57 | Website https://collplant.com |
Full time employees 57 | Website https://collplant.com | ||
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The company's products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. It offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound healing flowable gel for the treatment of chronic and acute wounds. The company also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. It has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.